Retraction
Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor–Positive Metastatic Breast Cancer: ALTERNATIVE
Paper Information
Record ID:
24119
Author(s):
Journal:
Publication Date:
December 15, 2017
Retraction Date:
August 21, 2020
(5.3 years years ago)
Subjects:
Broad Categories:
Medicine
Medicine
Institutions:
- The Royal Marsden NHS Foundation Trust, London
- Novartis Pharmaceuticals UK Limited, Frimley, United Kingdom
- Centro de Referência da Saúde da Mulher
- Hospital Israelita Albert Einstein, São Paulo, Brazil
- Seoul National University College of Medicine, Seoul
- National Cancer Center, Gyeonggi-do, Korea
- Regional Oncology Dispensary, Arkhangelsk
- N.N. Blokhin Russian Cancer Research Center, Moscow, Russia
- Galina Kurteva, University Cancer Center Hospital, Sofia, Bulgaria
- University of Southern California, Los Angeles, CA
- Aichi Cancer Center Hospital, Aichi, Japan
- Novartis Pharma AG, Basel, Switzerland
- Northwestern University, Chicago, IL
Countries:
Article Type:
Publisher:
American Society of Clinical Oncology
Open Access:
No
PubMed ID:
Retraction PubMed ID:
Retraction Details
Retraction Reasons:
Nature of Retraction:
Retraction
Retraction Notice:
10.1200/JCO.20.02029Additional Notes:
see also: https://ascopubs.org/doi/abs/10.1200/JCO.20.01894;
Citations (157)
157
Total Citations109
Post-Retraction(69.4%)
47
Pre-Retraction1
Same DayPost-Retraction Citation Analysis
0
Within 30 days
28
Within 1 year
60
After 2+ years
1678
Days since retraction (latest)
Combination therapies for the treatment of HER2-positive breast cancer: current and future prospects
Mariana Brandão, Noam Pondé, Francesca Poggio et al. (7 authors)
Expert Review of Anticancer Therapy
Published: May 2018
39 citations
39 citations
823 days before retraction
Treatment of advanced HER2-positive breast cancer: 2018 and beyond
Noam Pondé, Mariana Brandão, Georges El-Hachem et al. (5 authors)
Cancer Treatment Reviews
Published: May 2018
135 citations
135 citations
841 days before retraction
Innovative Strategies: Targeting Subtypes in Metastatic Breast Cancer
Mark D. Pegram, Yu Zong, Clinton Yam et al. (5 authors)
American Society of Clinical Oncology Educational Book
Published: May 2018
11 citations
11 citations
843 days before retraction
Chemotherapeutic agents for the treatment of metastatic breast cancer: An update
Mariam Abotaleb, Peter Kubatka, Martin Čaprnda et al. (10 authors)
Biomedicine & Pharmacotherapy
Published: Mar 2018
164 citations
164 citations
883 days before retraction
Targeting HER2 by Combination Therapies
Ana Ruiz-Sáenz, Mark M. Moasser
Journal of Clinical Oncology
Open Access
Published: Jan 2018
15 citations
15 citations
934 days before retraction
Metastatic Hormone and Her-2 Positive Breast Cancer: A Community Approach
Ida Micaily
International Journal of Clinical Oncology and Cancer Research
Open Access
Published: Jan 2018
1 citation
1 citation
963 days before retraction
Treatment of HER2-Overexpressing Metastatic Breast Cancer
Adnan Aydıner
Breast Disease
Published: Jan 2016
1 citation
1 citation
1694 days before retraction
Quick Stats
Total Citations:
157
Years Since Retraction:
5.3 years
Open Access:
No
Last Checked:
Jul 24, 2025